Treatment with venetoclax, etomoxir, or ST1326 led to marked suppression of proliferation in THP1# with GFI1B-KD and murine MLL/AF9 AML cells with Gfi1b-KO, without affecting cell viability (Fig. 7a, b and Supplementary Fig. S10d). Here, KMT2A is linked to acute myeloid leukemia.